NEUWAY Pharma And Cobra Biologics Ltd. Collaborate To Develop GMP Grade Engineered Protein Capsules (EPCs) Manufacturing Process
Collaboration supports GLP toxicity studies and initiation of clinical development for treatment of Progressive Multifocal Leukoencephalopathy
Keele, UK and Bonn, Germany, 11 October 2016: Cobra Biologics Ltd, an international CDMO of biologics and pharmaceuticals, and NEUWAY Pharma GmbH, a biopharmaceutical company developing drugs for the treatment of severe orphan CNS diseases, announce today the conclusion of a Service Agreement to develop a manufacturing process for the production of GMP grade material of Engineered Protein Capsules (EPCs) using SF9 cells and subsequent baculovirus infection. The material will be used by NEUWAY for the conduct of GLP toxicity studies and initiation of clinical development in the treatment of Progressive Multifocal Leukoencephalopathy, a very severe neurodegenerative CNS disease. NEUWAY Pharma also uses its EPCs as a CNS Drug Delivery Platform by filling them with active drug substances.
Dr Heiko Manninga, Chief Scientific Officer (CSO) and Managing Director of NEUWAY Pharma commented: “The initiation of GMP development is an important step towards qualification of EPCs for clinical development. We are very happy that we have gained Cobra Biologics as partner for the GMP manufacturing of Engineered Protein Capsules.”
Peter Coleman, CEO Cobra Biologics commented: “We are very pleased to be manufacturing NEUWAY Pharma’s EPCs for what is a rare but serious disease, often resulting in severe disability or death. With Cobra’s 17 years of virus production experience we hope this is just the beginning of our collaboration.”
For more information visit on Neuway Pharma visit www.neuway-pharma.com and for Cobra Biologics, www.cobrabio.com
Keele, UK and Bonn, Germany, 11 October 2016: Cobra Biologics Ltd, an international CDMO of biologics and pharmaceuticals, and NEUWAY Pharma GmbH, a biopharmaceutical company developing drugs for the treatment of severe orphan CNS diseases, announce today the conclusion of a Service Agreement to develop a manufacturing process for the production of GMP grade material of Engineered Protein Capsules (EPCs) using SF9 cells and subsequent baculovirus infection. The material will be used by NEUWAY for the conduct of GLP toxicity studies and initiation of clinical development in the treatment of Progressive Multifocal Leukoencephalopathy, a very severe neurodegenerative CNS disease. NEUWAY Pharma also uses its EPCs as a CNS Drug Delivery Platform by filling them with active drug substances.
Dr Heiko Manninga, Chief Scientific Officer (CSO) and Managing Director of NEUWAY Pharma commented: “The initiation of GMP development is an important step towards qualification of EPCs for clinical development. We are very happy that we have gained Cobra Biologics as partner for the GMP manufacturing of Engineered Protein Capsules.”
Peter Coleman, CEO Cobra Biologics commented: “We are very pleased to be manufacturing NEUWAY Pharma’s EPCs for what is a rare but serious disease, often resulting in severe disability or death. With Cobra’s 17 years of virus production experience we hope this is just the beginning of our collaboration.”
For more information visit on Neuway Pharma visit www.neuway-pharma.com and for Cobra Biologics, www.cobrabio.com